SLITRK3 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:22865, HGNC:23501, MIM:609679, NM_001318810, NM_001318811, NM_014926, NP_001305739, NP_001305740, NP_055741, SLIT and NTRK like family member 3, SLITRK3

Id:ENSG00000121871

Entrez:22865

Ensembl:ENSG00000121871

Description:SLIT and NTRK like family member 3

This gene encodes a member of the Slitrk family of structurally related transmembrane proteins that are involved in controlling neurite outgrowth. The encoded protein contains two leucine-rich repeat (LRR) domains and a C-terminal domain that is partially similar to Trk neurotrophin receptor protein. Enhanced expression of this gene was found in tissue from several different types of tumors. Alternative splicing results in multiple transcript variants, all encoding the same protein. [provided by RefSeq, Jan 2016]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View SLITRK3's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with SLITRK3.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using SLITRK3.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for SLITRK3.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with SLITRK3.

Results found

Linked to

	Label	Description
	GSE102505 5 V 0 TUNICAMYCIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 6 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE226285 3 V 0 GLUTATHIONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE101239 5 V 6 VALPROIC ACID MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE139987 1 V 0 ROSIGLITAZONE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE146687 2 V 5 ERIBULIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 0 V 4 PALMITIC ACID HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE220097 4 V 1 ENZALUTAMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE115395 2 V 4 ENZALUTAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE199538 GSE199539 enzalutamide 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE102505 5 V 0 TUNICAMYCIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 6 v 11 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE226285 3 V 0 GLUTATHIONE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE101239 5 V 6 VALPROIC ACID MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE139987 1 V 0 ROSIGLITAZONE MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE146687 2 V 5 ERIBULIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 0 V 4 PALMITIC ACID HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE220097 4 V 1 ENZALUTAMIDE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE115395 2 V 4 ENZALUTAMIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE199538 GSE199539 enzalutamide 2 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.